

PATENT SPECIFICATION

997,975



Date of Application and filing Complete
Specification: January 31, 1964.

Complete Specification Published: July 14, 1965.

© Crown Copyright 1965.

997,975

No. 4146164

Index at Acceptance:—A5 B (1D, 1S, 2D, 2S).

Int. Cl.:—A 61 k 3/00.

COMPLETE SPECIFICATION

NO DRAWINGS

Pharmaceutical Compositions Containing a Cresol or a Mixture of Cresols

I, ARISTOTELIS PAPAGEORGIOU-LAMBOS of 4 Monis Dohiarou Street, Athens, Greece, a Greek subject, do hereby declare the invention, for which I pray that a patent may be granted to me, and the method by which it is to be performed, to be particularly described in and by the following statement:

This invention relates to novel pharmaceutical compositions useful in the treatment of certain conditions caused by pathogenic micro organisms, viruses, cocci microbes, and parasites and also in the treatment of fungi and allergies.

The cresols (*o*-cresol, *m*-cresol and *p*-cresol) are known to have anti-bacterial properties (cf Martindales Extra Pharmacopica, 24th Edition, Volume 1, page 1017) but their use for this purpose has been limited in practice. I have now discovered that when the cresols are used in conjunction with strontium chloride (SrCl_2) as will hereinafter be more fully described the anti-bacterial and anti-microbial properties of the cresols are enhanced. It is an object of the present invention to provide a novel pharmaceutical composition containing a cresol or a mixture of cresols and strontium chloride, which composition has synergistic properties and is useful as an anti-bacterial agent in the treatment of certain conditions.

Thus, in accordance with the invention, there is provided a pharmaceutical composition for external and internal use comprising strontium chloride and one or more of *o*-cresol, *m*-cresol and *p*-cresol, and a pharmaceutically acceptable carrier therefor.

[Price 4s. 6d.]

Laboratory and clinical tests have shown that the anti-bacterial and anti-microbial properties of the novel compositions in accordance with the invention are considerably enhanced compared with those possessed either by any of the cresols alone or by any admixture of the cresols. Further the compositions of the invention are effective in the prevention of inflammations.

The quantities of the two active ingredients, i.e. the cresol, or mixture of cresols and the strontium chloride, in the composition will depend, as will be clearer hereinafter, on the intended use of the composition and method of application in any given case, but in most cases the composition will contain between 6 and 20% by weight strontium chloride and between 1 and 6% by weight of the cresol or cresols.

The method of preparing the compositions in accordance with the invention preferably comprises forming an aqueous solution (using distilled water) of the two active ingredients by conventional dissolution techniques followed by filtration of the solution. For some purposes the solution may be used as such, or in other cases further conventional pharmaceutically acceptable carriers, e.g. lanolin may be added to the solution to produce, for example, pastes, creams and ointments.

Examples of typical compositions in accordance with the invention for administration by the route indicated are as follows. (the percentages given for the active ingredients are by weight based on the total weight of the composition).

WHAT I CLAIM IS:—

1. A pharmaceutical composition for external and internal use comprising strontium chloride and one or more of *o*-cresol, *m*-cresol and *p*-cresol, and a pharmaceutically acceptable carrier therefore. 5
2. A pharmaceutical composition according to claim 1 comprising an aqueous solution of strontium chloride and one or more of *o*-cresol, *m*-cresol and *p*-cresol. 10
3. A pharmaceutical composition according to claim 1 or claim 2 and containing between 6 and 20% by weight strontium chloride and between 1 and 6% by weight of one or more of *o*-cresol, *m*-cresol and *p*-cresol. 15
4. A pharmaceutical composition according to claim 1 for external and internal use comprising an aqueous solution containing 6% by weight of strontium chloride and 1% by weight of *p*-cresol. 20
5. A pharmaceutical composition according to claim 1 for injections comprising an aqueous solution containing 10% by weight strontium chloride and about 1% by weight of *p*-cresol. 25
6. A pharmaceutical composition according to claim 1 in the form of an eye ointment containing 20% by weight of strontium chloride and 2.5% by weight of a mixture of *o*-, *m*-, and *p*-cresols. 30
7. A pharmaceutical composition according to claim 1 in the form of an ointment for external applications containing 20% by weight of strontium chloride and 6% by weight of a mixture of *o*-, *m*- and *p*-cresols. 35
8. A pharmaceutical composition according to claim 1 in the form of a cream containing 20% by weight of strontium chloride and 4% by weight of *p*-cresol. 40
9. A pharmaceutical composition according to claim 1 in the form of a hair lotion containing 7% by weight of strontium chloride and 6% by weight of *o*-cresol. 45
10. A pharmaceutical composition according to claim 1 in the form of a toothpaste containing 20% by weight strontium chloride and 4% by weight of *p*-cresol. 45
11. A method of preparing a pharmaceutical composition according to any preceding claim comprising forming an aqueous solution containing strontium chloride and one or more of *o*-, *m*- and *p*-cresol and thereafter if desired, diluting with water or mixing the solution with one or more further pharmaceutically acceptable carriers. 50
12. A pharmaceutical composition according to claim 1 substantially as hereinbefore described. 60
13. A pharmaceutical composition whenever prepared by a method according to claim 11. 60

TREGGAR, THIEMANN & BLEACH,
Chartered Patent Agents,
Melbourne House,
Aldwych,
London, W.C.2.
Agents for the Applicant(s).